Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
Last trade$3.30
Day change-$0.11 (-3.23%)
Day range$3.28 – $3.50
Volume277,839
Market cap$272M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$272.13M
Price / earnings
—
Price / book
2.03×
Price / sales
12.14×
EV / sales
10.96×
EV / EBITDA
-3.74×
Profitability
Earnings per share
-$0.76
Return on assets
-31.94%
Return on equity
-45.23%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
4.07×
Quick ratio
4.07×
Cash ratio
0.69×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$33.26M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PRLD, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$5.7M
$4.58M
$5.64M
$6.5M
$0
$0
$4M
$3M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$5.7M
$4.58M
$5.64M
$6.5M
$0
$0
$4M
$3M
Selling, general and administrative
$5.03M
$5.16M
$5M
$5.21M
$6.41M
$5.79M
$6.21M
$7.92M
Research and development
$16.13M
$13.6M
$17.99M
$21.71M
$25.78M
$28.82M
$31.62M
$29.46M
Total operating expenses
$21.16M
$18.76M
$22.99M
$26.92M
$32.19M
$34.61M
$37.83M
$37.38M
Operating income
-$15.45M
-$14.18M
-$17.35M
-$20.42M
-$32.19M
-$34.61M
-$33.83M
-$34.38M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$13.92M
-$10.39M
-$16.46M
-$19.73M
-$31.23M
-$32.09M
-$28.73M
-$32.27M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$13.92M
-$10.39M
-$16.46M
-$19.73M
-$31.23M
-$32.09M
-$28.73M
-$32.27M
Net income attributable to common shareholders
-$13.92M
-$10.39M
-$16.46M
-$19.73M
-$31.23M
-$32.09M
-$28.73M
-$32.27M
EBITDA
-$15.1M
-$13.79M
-$16.93M
-$19.99M
-$31.76M
-$34.17M
-$33.34M
-$33.97M
Basic earnings per share
-$0.14
-$0.13
-$0.21
-$0.26
-$0.41
-$0.42
-$0.38
-$0.43
Diluted earnings per share
-$0.14
-$0.13
-$0.21
-$0.26
-$0.41
-$0.42
-$0.38
-$0.43
Recent news
Company coverage with links to the original publishers.
Prelude Therapeutics reported a Q3 loss of $0.12 per share, beating the consensus estimate of $0.14 loss by 14.29%. Revenue came in at $5.65 million, surpassing estimates by 12.94%, though down from $6.5 million year-over-year. The company has a Zacks Rank #2 (Buy) rating with favorable estimate revision trends. Stock has gained 19% year-to-date versus S&P 500's 10.5% gain.
Merck KGaA is expected to report declining earnings and revenues for Q3 2026 with an Earnings ESP of 0% and Zacks Rank #3, making it difficult to predict an earnings beat. In contrast, Prelude Therapeutics shows a positive Earnings ESP of +9.72% combined with a Zacks Rank #2 (Buy), suggesting it is likely to beat consensus estimates, with a history of beating estimates in the last four quarters.
Prelude Therapeutics (PRLD) is expected to beat Q3 2026 earnings estimates with a positive Earnings ESP of +9.72% and Zacks Rank #2. The company is projected to report a quarterly loss of $0.14 per share (improved 46.2% year-over-year) on revenues of $5 million (down 23.1%). With a strong history of beating consensus estimates in the last four quarters, PRLD appears positioned for an earnings beat.
Tenet Healthcare is projected to report Q3 2026 earnings of $4.60 per share (up 24.3% YoY) on revenues of $5.47 billion (up 3.5% YoY). The company's Ambulatory Care segment is expected to drive growth with 8.4% revenue increase and 9.3% adjusted EBITDA growth. However, hospital patient days may decline 3.7% with increased utilization costs partially offsetting gains. The stock has an Earnings ESP of +11.11% and Zacks Rank #3, suggesting a likely earnings beat.
Prelude Therapeutics announced preclinical data for PRT13722, a first-in-class oral KAT6A degrader showing complete tumor regressions in HR+/HER2- breast cancer models with improved hematological safety compared to existing approaches. The company remains on track to file an IND application by mid-2026 and initiate clinical trials in the second half of 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.